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Atrial fibrillation is a highly prevalent cardiac arrhythmia. It is associated with nu-
merous co mobilities. Approximately 30% of diabetic patients have atrial fibrillation
and 15% of atrial fibrillation regulation patients have diabetes mellitus. Diabetes
increases the likelihood of the development of atrial fibrillation and contributes to
the high risk of thromboembolism seen in patients with both diabetes and atrial fi-
brillation. Chronic kidney disease is often a consequence of diabetes and presents an
additional challenge to the management of patients with both atrial fibrillation and
diabetes. All non-vitamin K oral anticoagulants are partially eliminated via the kid-
ney and must be carefully prescribed according to strict dosing schedules to avoid
anticoagulation overdose. However, NOACs have the advantage of being associated
with less progressive impairment of renal function compared with vitamin K antago-
nist therapy in both diabetics and non-diabetics. Otherwise, diabetic patients benefit
from NOAC therapy as opposed to vitamin K antagonists to a similar extent as
patients without diabetes. This review deals with anticoagulation treatment in
patients with fibrillation and diabetes mellitus, often complicated by progressive re-
nal impairment.
Introduction
The prevalence of atrial fibrillation continues to increase
because of better case recognition and improved survival
of patients already with atrial fibrillation or with comorbid-
ities which are likely to lead to atrial fibrillation. Among
these comorbidities are diabetes and chronic kidney dis-
ease (CKD), both of which promote the development of
atrial fibrillation, worsen outcomes associated with atrial
fibrillation, and present challenges with the treatment of
the arrhythmia with anticoagulant therapy. This review fo-
cuses on the prognosis and management of atrial
fibrillation and its complications in patients with diabetes,
impaired renal function, or both conditions.
Diabetes
The global burden of diabetes is currently estimated to af-
fect 463 million individuals or 1 in 11, according to the
International Diabetes Federation, and projections esti-
mate a 48% increase in the prevalence to 700million people
by 2045.1 The vast majority (80–90%) have type 2 diabetes.
Diabetes predisposes to the development of atrial fibrilla-
tion, thus in the Framingham study, the odds for atrial fi-
brillation was increased 40% for men and 60% for women.2
In people with atrial fibrillation not receiving anticoagula-
tion, diabetes is a risk factor for ischaemic stroke3–5
(Figure 1).
In addition to the increased risk for atrial fibrillation, di-
abetes is associated with a two- to four-fold increased risk*Corresponding author. Tel: þ44 753 853 9540, Email: jcamm@sgul.ac.uk
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for atherosclerotic cardiovascular disease (CVD) compared
to the background population, and 30–40% with diabetes
are affected by chronic kidney disease characterized by in-
creased albuminuria and/or decreased glomerular filtra-
tion rate (GFR; or diabetic kidney disease, DKD) (Figure 1).
The presence of kidney disease in diabetes increases the
risk of CVD and the combination is associated with excess
mortality. Increasing albuminuria or decreasing GFR
increases the risk of CVD and mortality6 and the risk for
end-stage kidney disease (ESKD). Furthermore, albumin-
uria and GFR levels form the basis on which chronic kidney
disease is staged according to the Kidney Disease Improving
Global Outcome guidelines.7 Early-onset DKD may shorten
life expectancy by 15years,8 and excess mortality in dia-
betes is primarily due to mortality in DKD9; with a six-fold
increased risk for mortality with albuminuria, and 15-fold
increased risk with albuminuria and reduced GFR.9
As already stated, the prevalence of atrial fibrillation is
increased in diabetes. It has been estimated that 15% of
subjects with diabetes have atrial fibrillation10 and con-
versely that 30% of atrial fibrillation patients have diabe-
tes, among a population from the ORBIT-AF (Outcomes
Registry for Better Informed Treatment of Atrial
Fibrillation) registry, a prospective, nationwide, outpatient
registry of people with incident and prevalent AF including
9749 subjects with atrial fibrillation.11 In a large electronic
health record database with administrative claims data,
one in three with atrial fibrillation had diabetes.12
Similarly, analysis of a large database including 293 124
individuals found diabetes to be a strong independent risk
factor with 100% increased odds for atrial fibrillation.13
Even the metabolic syndrome, with a cluster of multiple
cardiovascular (CV) risk factors including hypertension,
obesity, dyslipidaemia, and dysglycaemia, often preceding
manifest diabetes, is associated with excess risk for atrial
fibrillation, and even more when combined with chronic
kidney disease.14
The prevalent combination of diabetes and atrial fibrilla-
tion is also reflected in the randomized controlled clinical
trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48)
investigating non-vitamin K oral anticoagulants (NOACs)
compared with warfarin, in subjects with non-valvular
atrial fibrillation, where 23–40% of subjects included had
diabetes.15 Diabetes has been shown to increase the risk of
incident AF,7 as it promotes maladaptive and pro-
fibrillatory structural (mediated by oxidative stress, ad-
vanced glycosylation end products, and connective tissue
changes), electromechanical, and autonomic nervous sys-
tem changes.16
Not only is diabetes associated with increased occur-
rence of atrial fibrillation but also based on follow-up of
11 140 type 2 diabetes subjects, the combination of diabe-
tes and atrial fibrillation is associated with increased risk
for death (61% increased risk) and major cerebrovascular
deaths (68% increased risk).17 This increased event rate
may be explained by the underlying pathophysiological
mechanisms where diabetes with hyperglycaemia and AF
contribute to the risk of stroke and thromboembolism via
partly shared pathophysiological pathways. Thus, both pro-
mote oxidative stress and inflammation which leads to en-
dothelial damage, increasing susceptibility to thrombus
formation. Also, diabetes and AF are independently associ-
ated with platelet and fibrinogen activation contributing
to changes in the blood constituents which also increases
the likelihood of thrombus formation. Adding the changes
in left atrial dimensions and abnormal flow and stasis fur-
ther increases the propensity for thromboembolism.16
This was supported and extended from the ORBIT-AF reg-
ister showing that patients with diabetes (30%) were youn-
ger, more likely to have hypertension, chronic kidney
Figure 1 Comorbid diabetes is highly prevalent and increases the risk of stroke and cardiovascular death in patients with atrial fibrillation. DM, diabetes
mellitus; HR, hazard ratio; GARFIELD, Global Anticoagulant Registry in the FIELD-Atrial Fibrillation; NOAC, non-vitamin K oral anticoagulant; ORBIT,
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; RCT, randomized controlled trial.
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disease, heart failure, coronary heart disease, and stroke.
Compared to patients without diabetes, patients with dia-
betes also had a lower Atrial Fibrillation Effects on Quality
of Life score of 80 (interquartile range, IQR: 62.5–92.6) vs.
82.4 (IQR: 67.6–93.5; P¼ 0.025) driven by the daily activi-
ties’ domain score, whereas the symptoms and treatment
concern domain scores were similar.
The overall use of anticoagulants (warfarin or dabiga-
tran) was significantly greater among people with diabe-
tes. The use of warfarin only was higher among those with
diabetes compared to those without diabetes (74.3% vs.
70.4%; P< 0.001) but the use of dabigatran was similar in
the two groups. Aspirin was more commonly used among
people with diabetes (46.5% vs. 43.4%; P¼ 0.006).
Diabetes was associated with higher mortality risk, includ-
ing overall [hazard ratio (HR): 1.63; 95% confidence inter-
val (CI): 1.04–2.56, for age < 70years vs. HR: 1.25; 95% CI:
1.09–1.44, for age  70years] and CV mortality (HR: 2.20;
95% CI: 1.22–3.98, for age< 70years vs. 1.24; 95% CI: 1.02–
1.51 for age  70years). Diabetes conferred a higher risk
of non-CV death, sudden cardiac death, hospitalization, CV
hospitalization, and non-CV and non-bleeding-related hos-
pitalization, but no increase in risks of thromboembolic
events, bleeding-related hospitalization, new-onset heart
failure (HF), and AF progression.11
In the ROCKET-AF study comparing rivaroxaban and war-
farin in nonvalvular atrial fibrillation in 14 264 subjects
with a prevalence of diabetes of 40%, a higher likelihood of
CV death was observed with diabetes with an HR of 1.44
(1.24–1.68).18 This study furthermore demonstrated that
the NOAC rivaroxaban gave similar protection against the
primary endpoint of stroke and systemic embolism as did
warfarin, without increasing overall major bleeding risk
(Figure 2). In addition, rivaroxaban provided a significant
benefit on the secondary outcome of CV death with an HR
of 0.80 (0.64–0.99) and a significant interaction with diabe-
tes (P¼ 0.037).
In the ARISTOTLE trial, there were similar benefits on re-
ducing stroke, decreasing mortality, and causing less intra-
cranial bleeding with apixaban compared to warfarin in
people with and without diabetes. People with diabetes re-
ceiving apixaban had lower rates of stroke and systemic
embolism (HR of 0.75, 95% CI 0.53–1.05), all-cause mortal-
ity (HR 0.83, 95% CI 0.67–1.02), CV mortality (HR 0.89, 95%
CI 0.66–1.20), intracranial haemorrhage (HR 0.49, 95% CI
0.25–0.95), and a similar rate of myocardial infarction (HR
1.02, 95% CI 0.62–1.67) compared with warfarin19
(Figure 2). In a real-world data study of a cohort of
n¼ 77 752 with atherosclerosis and atrial fibrillation, the
risk for major adverse CV events (CV death or hospitaliza-
tion with a primary billing code for myocardial infarction or
ischaemic stroke) was also increased with diabetes
(n¼ 37 114) with an HR of 1.11 (1.05–1.18).20
The four Phase 3 studies comparing NOACs with warfarin
were meta-analysed and the analysis demonstrated a re-
duction in stroke/systemic embolism in diabetic [risk ratios
(RR) 0.80, 95% CI 0.68–0.93; P¼ 0.004] and nondiabetic
patients (RR 0.83, 0.73–0.93; P ¼ 0.001; P for interaction
0.72). In general, there was no interaction between diabe-
tes and NOAC effect in AF. There was a reduction in vascu-
lar mortality in diabetes with NOACs compared to
warfarin, which was not seen in non-diabetic subjects, but
the P-value for interaction was not significant21 (Figure 2).
Observational data from registries have found similar
results. A study using MarketScan claims data demon-
strated in a cohort of 77 752 with coronary artery disease
or at least three risk factors, and NVAF, of whom 48% had di-
abetes, that AF patients receiving an oral anticoagulant
(OAC) compared to patients without OAC, were less likely
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Figure 2. Outcomes of diabetic patients in Phase 3 non-vitamin K oral anticoagulants versus warfarin(19,70–72). CV ¼ cardiovascular; ICH ¼ intra cranial
hemorrhage SE ¼ systemic embolus.
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(8.9% vs 11.6%, P< 0.0001) including ischaemic stroke
(5.4% vs. 6.7%, P< 0.0001).22 In another study using
MarketScan claims data for a cohort of only type 2 diabetes
with non-valvular AF (NVAF), 10 700 users of the NOAC
rivaroxaban and 13 946 users of warfarin were identified.
The study found rivaroxaban was associated with a 25%
(95% CI 4–41) reduced risk of MACE compared to warfarin.
Major bleeding risk did not significantly differ between
cohorts (HR 0.95).23
When applying the CHA2DS2-VASc score to assess risk for
stroke in atrial fibrillation the D (diabetes) is defined as
fasting blood glucose >7mmol/L, or treatment with oral
hypoglycaemic drugs, and/or insulin.24 It has now been in-
cluded in the ESC guideline that the excess risk for stroke
associated with diabetes, is very similar in type 1 and type
2 diabetes except perhaps for a slightly increased risk in
type 2 diabetes compared to type 1 in patients <65years
of age.25 The risk for stroke increases with longer diabetes
duration, as well as with more diabetes comorbidities such
as retinopathy.24,26,27 In diabetes guidelines, diabetes is
also diagnosed by elevated haemoglobin A1c >6.5% or
48mmol/L, which does not require fasting and this could
be an alternative.
The impact of diabetes therapy on the risk for stroke and
AF has been debated. Although the SGLT2 inhibitor empa-
gliflozin was associated with a reduction in major adverse
CV events in the CV outcome study EMPA-REG, a non-
significant trend towards an increase in stroke was seen,28
but this has not been seen in other SGLT2 inhibitor studies.
With the GLP1 receptor agonists, a reduction in fatal and
non-fatal stroke has been seen in the CV outcome studies
HR 0.84 (95% CI 0.76–0.93).29 This was not evaluated in the
context of atrial fibrillation. It has been suggested that
metformin and pioglitazone may reduce the risk for AF.30
Recently, it was suggested that the SGLT2 inhibitor
dapagliflozin-reduced occurrence of AF in type 2 diabetes
in the CVoutcome study DECLARE-TIMI 58. Dapagliflozin re-
duced the risk of AF/AFL events by 19% [264 vs. 325 events;
7.8 vs. 9.6 events per 1000 patient-years; HR 0.81 (95% CI
0.68–0.95); P¼ 0.009]. The reduction in AF/AFL events was
consistent regardless of the presence or absence of a his-
tory of AF/AFL or ASCVD at baseline. Dapagliflozin also re-
duced the total number (first and recurrent) of AF/AFL
events incidence rate ratio, 0.77 (95% CI 0.64–0.92);
P¼ 0.005).31 This finding was exploratory but very inter-
esting as the SGLT2 inhibitors are now increasingly recom-
mended for patients with type 2 diabetes,32 but the finding
should be confirmed in additional studies. This has not
been seen with other glucose-lowering medications, and
intensive glycaemic control does not affect the risk for
AF.24
A prevalent complication in diabetes is the diabetic foot,
or major adverse limb events (MALE) in clinical studies. In
diabetes management, this is the most expensive compli-
cation related to diabetes. Interestingly, NOACs were
found to reduce the risk of MALE in atrial fibrillation
patients with diabetes when compared with warfarin. This
was seen in a retrospective claims’ analysis in patients with
atrial fibrillation and comorbid diabetes. The study identi-
fied 10 700 people treated with rivaroxaban and 13 946
patients treated with warfarin. At baseline, 11% of people
had peripheral artery disease, 5.1% had coronary artery
disease, and 5.1% had a prior MALE. Compared to warfarin,
rivaroxaban was associated with a 63% (95% CI 35–79) re-
duced risk of MALE. For major limb amputations, the re-
duced risk with rivaroxaban compared with warfarin was
80% (95% CI 31–94).23 Similar results were found based on
an analysis from the Taiwan National Health Insurance
Research Database, where a total of 20 967 and 5812 con-
secutive AF patients with diabetes taking NOACs and war-
farin, respectively were identified. Here, NOAC treatment
was associated with a lower risk ofmajor adverse CVevents
[adjusted HR: 0.88 (95% CI 0.78–0.99), P¼ 0.028], major
adverse limb events [HR: 0.72 (95% CI 0.57–0.92);
P¼ 0.0083], and major bleeding [HR: 0.67 (95% CI 0.59–
0.76); P< 0.0001] compared to warfarin.33
Given the limitation of non-randomized observations,
this needed to be confirmed in a pre-specified subgroup of
people with peripheral artery disease and diabetes in the
Phase III COMPASS study which compared low-dose rivarox-
abanþ aspirin to aspirin alone in 7470 participants with pe-
ripheral artery disease.34 In the COMPASS study,
rivaroxaban 2.5mg twice daily with aspirin 100mg once
daily compared to aspirin alone, reduced MALE including
major amputation with an HR of 0.54 (95% CI 0.35–0.82;
P¼ 0.0037).34 The effect was smaller in people with co-
morbid diabetes, but there was no significant interaction
with diabetes.35
Thus, diabetes is prevalent, associated with increased
risk for atrial fibrillation, and also other adverse CV and
kidney outcomes. It may be argued that diabetes in atrial
fibrillation should be considered more than ‘1’ point in the
CHA2DS2-VASc risk score.
Impact of chronic kidney disease in patients with
diabetes and atrial fibrillation
It is well established that patients with NVAF and chronic
kidney disease (CKD) are at a higher risk of ischaemic
stroke,24 although the presence of CKD (or renal impair-
ment) unlike the diagnosis of diabetes is not implemented
in the currently recommended risk stratification.24 Indeed,
the inclusion of renal dysfunction into the CHA2DS2-VASc
score lacks substantial additive predictive value.36 This is
likely because the predictive value of CKD is already cap-
tured by other score components within CHA2DS2-VASc that
strongly associate with CKD, most importantly age, hyper-
tension, and diabetes. Hence, hypertension and diabetes
represent the most common global causes of CKD,37 while
the prevalence of both CKD and diabetes associates with
age. In diabetes and CKD, several overlapping pathophysio-
logical factors related to alterations in the three compo-
nents of Virchow’s triad (changes in blood constituents,
blood flow, and vessel wall and/or atrial tissue) contribute
to the prothrombotic state in coexisting AF with either CKD
or diabetes.38,39
Interestingly, diabetic retinopathy did not emerge as an
independent predictor for either stroke or severe bleed-
ing,26 whereas regardless of AF, patients with CKD are per
se at increased risk of bleeding due to several mechanisms
that contribute to a prohaemorrhagic state.38,39 During
anticoagulation, the increased bleeding risk may be further
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exacerbated by the significant effects of renal impairment
on the pharmacokinetics and/or pharmacodynamics of an-
ticoagulant drugs.40 Hence, abnormal renal function de-
fined as chronic dialysis, renal transplantation, or serum
creatinine 200lmol/L (which would relate to a CrCl of
about 25 or 30mL/min in a female or male patient at the
age of 70years and body weight of 70kg) is a parameter ac-
counting for 1 point in the HAS-BLED score41 that is recom-
mended as a tool for bleeding risk assessment in patients
with AF.24
Against this background, the use of NOACs and particu-
larly their safety in patients with CKD was followed with
great interest from the beginning, because the four avail-
able NOACs for anticoagulation in AF are all to varying
degrees eliminated by the kidney.40 In this regard, it was
reassuring that in patients with renal impairment the
safety and efficacy of NOAC compared with warfarin treat-
ment was consistent with patients without CKD in the four
landmark NOAC RCTs.42–45 However, patients with a creati-
nine clearance (CrCl) <25–30mL/min as estimated with
the Cockcroft–Gault equation were generally excluded
from these pivotal Phase 3 RCTs. Consequently, adequate
safety and efficacy data are lacking in patients with CKD
stage 4 (CrCL of 15–29mL/min) and CKD stage 5, i.e. ESKD
(CrCL < 15mL/min) including the relatively large group of
patients with diabetes and advanced CKD.37 Nevertheless,
NOAC use in AF patients with CKD and a CrCl greater than
30mL/min is based on evidence from RCTand thus not re-
stricted in this vulnerable patient group.24,40
The same considerations may apply to stroke risk assess-
ment and selection of oral anticoagulants in these patients
including patients with DKD and a CrCl >30mL/min.
Moreover, pharmacokinetic data indicated that the change
in NOAC plasma levels for the three factor Xa inhibitors
apixaban, edoxaban, and rivaroxaban in severe CKD (CrCl
15–30mL/min) were similar to patients with moderate re-
nal impairment and led to their approval in patients with
severe CKD.46 Accordingly, reduced dosing regimens for
these drugs are feasible options for anticoagulation in
patients with severe non-ESKD.24,46
The use of OAC in patients with ESKD on maintenance di-
alysis is still a matter of debate.38,39,47 In Europe, NOACs
are not approved and not recommended in patients with
CrCl <15mL/min.24,46 In this regard, it is important to em-
phasize that although the FDA does mention the usage of
oral anticoagulant in patients on dialysis with recom-
mended dosing for VKA, apixaban, and rivaroxaban, the
FDA itself has not endorsed this indication for use in this
population as recently noted.39
Data from observational studies suggest a possible reduc-
tion in the risk of bleeding in patients with ESKD who take
an NOAC compared to VKA48,49 and possibly a similar risk of
embolic and major bleeding events associated with the
treatment with apixaban and rivaroxaban.50 Currently,
there are at least three ongoing RCTs that are designed as
safety (Phase 2) trials enrolling relatively low numbers
(150–855) patients on dialysis including patients with dia-
betes. They will compare NOACs with VKAs or oral anticoa-
gulation with no use anticoagulants (NCT03987711,
NCT02933697, and NCT02886962). The challenge to con-
duct studies in this setting has been recently highlighted by
the early termination of the RENAL-AF trial, investigating
apixaban vs. warfarin in AF patients on haemodialysis, with
inconclusive data on relative stroke and bleeding rates.51
Observational studies in AF patients and renal
outcomes
Of note, unlike AF patients on dialysis, to the best of our
knowledge, there are no ongoing RCTs to explore the im-
pact of OAC with VKA and NOACs in patients with non-
dialysis advanced CKD particularly in patients with Stage 4
CKD (CrCl < 30mL/min). We thus still face an unmet need
of evidence from RCTs in this vulnerable patient cohort.
Nevertheless, because there is a progressively increased
risk of both ischaemic stroke and haemorrhage as renal
function declines it is important to evaluate the
Figure 3. Factors for arterial calcification and kidney injury: differential impact of anticoagulation with Vitamin K antagonists versus non-vitamin K
antagonists (NOACs). CKD ¼ chronic kidney disease, ECM ¼ extracellular matrix; RAAS ¼ renin-angiotensin-aldosterone system.
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effectiveness of anticoagulation in this setting, which is
the aim of ongoing prospective registries with blinded out-
come adjudication in Europe (XARENO, NCT02663076) and
Eastern Asia (XARENAL, NCT03746301).Importantly, there
is a substantial number of observational studies available
in this condition that include by virtue of the relatively
high prevalence also AF patients with CKD and diabetes.
This is important since a progressive decline in renal func-
tion is often observed in diabetes particularly in patients
with pre-existing CKD, which associates with a poor
prognosis.52
Increased vascular calcification processes for which dia-
betes and CKD share complementary pathophysiology53,54
has been identified as a possible mechanism contributing
to the decline in renal function in patients with diabetes
and CKD (Figure 3). The latter is frequently worsened in
the presence of other risk factors for calcification, such as
advanced age and hypertension,54 which are very common
in AF patients. While in patients with CKD, a disturbance in
calcium–phosphate balance, accumulation of uremic tox-
ins, and severe vitamin K deficiency have been implicated
in the pathogenesis of vascular calcification, several other
signalling pathways in addition to elevated glucose levels
play a role in diabetes although the mechanisms are still
not fully understood53,54 (Figure 3). In anticoagulated AF
patients and particularly in patients with comorbid CKD
and diabetes, the use of VKA may aggravate vascular calci-
fication55 including calcification in the vascular bed of the
kidney, thereby contribute to worsening renal function in
these patients.56,57 This is mechanistically based on inhibi-
tion of the vitamin K-dependent gamma-glutamyl carbox-
ylation that applies not only to the clotting factors II, VII,
IX, and X but also to the other vitamin K dependent
gamma-carboxyglutamic acid (Gla) proteins including the
matrix Gla protein (MGP).54,58 Matrix Gla protein, which is
in the vascular wall mainly produced in vascular smooth
muscle cells, represents the most potent endogenous pro-
tector against vascular calcification and its diminished
function has been linked to vascular calcification during
VKA treatment.58 In contrast, NOACs, such as the factor Xa
inhibitor rivaroxaban, due to their different mode of action
do not only lack this negative effect, but may even provide
beneficial protective effects against vascular injury and re-
nal functional decline by decreasing vascular inflamma-
tion, remodelling, and vascular calcifications through
reduced protease-activated receptor (PAR) signalling via
PAR-1 and PAR-259,60 (Figure 3).
The possible differential impact of anticoagulation with
either VKA vs. NOACs provided the biological basis to inves-
tigate the effects of these treatments for renal outcomes
in addition to thromboembolic and bleeding events in AF
patients with diabetes in retrospective real-world studies.
Accordingly, a recent study using United States IBM
MarketScan data included patients with NVAF and diabetes
that newly initiated on rivaroxaban (N¼ 10 017) or warfa-
rin (N¼ 11 665).61 Patients with Stage 5 CKD or undergoing
haemodialysis at baseline were excluded and baseline
covariates between cohorts were adjusted using inverse
probability of treatment weighting based on propensity
scores. In comparison to warfarin, rivaroxaban was associ-
ated with lower risks of acute kidney injury (AKI) events
(HR 0.83, 95% CI 0.74–0.92) and development of Stage 5
CKD or need for haemodialysis (HR 0.82, 95% CI 0.70–0.96).
The protective effect in favour of rivaroxaban was particu-
larly pronounced in the subgroup of diabetic patients with
pre-existing Stage 3–4 CKD for both AKI (HR 0.63, 95% CI
0.49–0.79) and the risk of stage 5 CKD or need for haemo-
dialysis (HR 0.66, 95% CI 0.46–0.94).61 A similar retrospec-
tive study on data from a claims database in Germany
evaluated confounder-adjusted risks for AKI and ESKD in
AF patients with diabetes who received rivaroxaban
(n¼ 6997) or the VKA phenprocoumon (n¼ 8545).62 The
relative risks for AKI was decreased by 28% (HR 0.72, 95% CI
0.53–0.97) and for ESKD by 68% (HR 0.32, 95% CI 0.19–0.53)
in AF patients with diabetes prescribed rivaroxaban vs.
phenprocoumon.
Despite the methodological limitations of these observa-
tional retrospective studies including potential residual
Figure 4. Differential impact of anticoagulation with VKA versus NOAC on renal outcomes in atrial fibrillation. AKI ¼ acute kidney injury; NOAC ¼ non-
vitamin K oral anticoagulant, VKA ¼ vitamin K oral anticoagulant.
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confounding due to the absence of randomization, it
appears that rivaroxaban treatment associates with a
lower risk of both AKI and progression to Stage 5 CKD or di-
alysis in diabetic patients with NVAF (Figure 4). Similar
results towards a benefit in reducing the risk for AKI and/or
progression to Stage 5 CKD were also obtained in other ret-
rospective real-world studies in the overall population of
AF patients that included also diabetic patients but were
not restricted to patients with comorbid diabetes.63,64
Apart from the generally increased risk of bleeding in
patients with AF with CKD, there are also concerns about
the risk of anticoagulation nephropathy (ARN) in these
patients.65,66 Anticoagulation nephropathy is character-
ized by profuse glomerular haemorrhage leading to renal
tubules filled with red cells and red cell casts resulting in
AKI.65,66 While ARN may develop in response to any antico-
agulant, including VKA and NOACs, it has been particularly
associated with overdosing of warfarin with INR levels
>3.65,66 Older patients with diabetes and CKD are particu-
larly prone to develop ARN that can trigger episodes of AKI
thatmay occurmore frequently in AF patients as previously
thought.66 Recurrences of these AKI episodes can in turn
accelerate the progression of CKD and are associated with
an increased mortality rate.67 Thus, although the patho-
genesis of AKI is multifactorial, ARN may contribute to AKI
events particularly in AF patients with CKD and diabetes. In
this regard, the observational evidence for a significant
risk reduction for AKI events by rivaroxaban vs. VKA may at
least in part be attributable to a decrease in the rate of
ARN.
Summary/conclusion: pending
In the recent 2020 ESC guidelines for the diagnosis and
management of atrial fibrillation developed in collabora-
tion with the European Association of Cardio-Thoracic
Surgery (EACTS), the importance of an integrated manage-
ment of AF patients was emphasized to deliver optimized
treatment.24 In this guidelines, a core element to guide
and simplify management represents the previously
suggested68 simple Atrial fibrillation Better Care (ABC) ho-
listic pathway (‘A’ Anticoagulation/Avoid stroke; ‘B’ Better
symptom management; ‘C’ Cardiovascular and Comorbid-
ity optimization).24 In the ABC pathway, optimal manage-
ment of comorbidities plays a pivotal role to improve
outcome in patients with AF. As discussed in this review, di-
abetes per se and even more so when associated with CKD
represents one of the most important comorbidities that
requires optimal management by guideline-directed ther-
apy.69 This is also acknowledged in the 2019 ESC Guidelines
on diabetes, pre-diabetes, and CVDs developed in collabo-
ration with the European Association for the Study of
Diabetes, by recommending that anticoagulation in all AF
patients with diabetes.69 This supports our notion that dia-
betes in atrial fibrillation should be considered more than
‘1’ score in the CHA2DS2-VASc score. In addition to the in-
creased risk for stroke, diabetes is frequently associated
with chronic kidney disease. It impacts choice of anticoa-
gulation as reviewed: NOAC provide similar or better pro-
tection against stroke compared to VKA, but reduced risk
for bleeding, and in addition rivaroxaban compared to VKA
provided benefit on CV mortality, MALE, and progression of
CKD.
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